• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

碳酸锂治疗情感障碍患者发作间期症状及复发的预测因素

Predictors of interepisode symptoms and relapse in affective disorder patients treated with lithium carbonate.

作者信息

Goodnick P J, Fieve R R, Schlegel A, Baxter N

出版信息

Am J Psychiatry. 1987 Mar;144(3):367-9. doi: 10.1176/ajp.144.3.367.

DOI:10.1176/ajp.144.3.367
PMID:3103474
Abstract

For 98 affective disorder patients receiving lithium prophylaxis for a mean of 45 months, number of interepisode symptoms correlated with relapse rate. Response to prophylaxis appeared highly determined by prelithium frequency of episodes and duration of lithium treatment.

摘要

对于98名接受锂盐预防性治疗平均45个月的情感障碍患者，发作间期症状的数量与复发率相关。预防性治疗的反应似乎高度取决于锂盐治疗前的发作频率和锂盐治疗的持续时间。

相似文献

1
Predictors of interepisode symptoms and relapse in affective disorder patients treated with lithium carbonate.碳酸锂治疗情感障碍患者发作间期症状及复发的预测因素
Am J Psychiatry. 1987 Mar;144(3):367-9. doi: 10.1176/ajp.144.3.367.
2
Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination.预防单相和双相情感障碍复发的药物治疗。美国国立精神卫生研究所协作研究小组比较碳酸锂、丙咪嗪及碳酸锂 - 丙咪嗪联合用药的报告。
Arch Gen Psychiatry. 1984 Nov;41(11):1096-104. doi: 10.1001/archpsyc.1983.01790220086014.
3
Lithium prophylaxis of depression in unipolar, bipolar II, and cyclothymic patients.锂盐对单相、双相Ⅱ型及环性心境障碍患者抑郁症的预防作用。
Am J Psychiatry. 1982 Jun;139(6):747-52. doi: 10.1176/ajp.139.6.747.
4
Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder.与 DSM-III 重度抑郁症和双相情感障碍中锂盐预防性治疗反应相关的因素。
Pharmacopsychiatry. 1985 Sep;18(5):309-13. doi: 10.1055/s-2007-1017387.
5
Lithium therapy and prophylaxis in unipolar manic-depressive illness.单相躁郁症的锂盐治疗与预防
Neurol Psychiatr (Bucur). 1988 Oct-Dec;26(4):271-9.
6
Alexithymia and somatic conditions in patients with affective illnesses during lithium prophylaxis.
Psychother Psychosom. 1988;49(1):1-5. doi: 10.1159/000288058.
7
The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizo-affective disorders.锂盐预防在双相和单相抑郁症及分裂情感性障碍中的有效性。
J Affect Disord. 1986 Nov-Dec;11(3):275-80. doi: 10.1016/0165-0327(86)90079-0.
8
A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.一项针对近期有躁狂或轻躁狂发作的双相I型障碍患者，使用拉莫三嗪和锂盐维持治疗的为期18个月的安慰剂对照试验。
Arch Gen Psychiatry. 2003 Apr;60(4):392-400. doi: 10.1001/archpsyc.60.4.392.
9
Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison.碳酸锂和丙咪嗪预防单相和双相II型疾病：一项前瞻性、安慰剂对照比较研究。
Arch Gen Psychiatry. 1982 Sep;39(9):1065-9. doi: 10.1001/archpsyc.1982.04290090053011.
10
Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders.双相 I 型和双相 II 型障碍中锂盐维持治疗抑郁和躁狂
Am J Psychiatry. 1998 May;155(5):638-45. doi: 10.1176/ajp.155.5.638.

引用本文的文献

1
A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder.双相情感障碍中锂盐反应临床预测因素的系统评价与荟萃分析。
Acta Psychiatr Scand. 2019 Aug;140(2):94-115. doi: 10.1111/acps.13062. Epub 2019 Jun 30.
2
Mindfulness-based cognitive therapy versus psychoeducational intervention in bipolar outpatients with sub-threshold depressive symptoms: a randomized controlled trial.基于正念的认知疗法与心理教育干预对伴有阈下抑郁症状的双相情感障碍门诊患者的疗效比较：一项随机对照试验
BMC Psychiatry. 2014 Aug 15;14:215. doi: 10.1186/s12888-014-0215-x.
3
Subsyndromal states in bipolar disorder.
双相障碍的亚综合征状态。
Indian J Psychiatry. 2010 Oct;52(4):367-70. doi: 10.4103/0019-5545.74314.
4
Long-term outcome of lithium prophylaxis in patients initially classified as complete responders.
Psychopharmacology (Berl). 1989;98(4):535-8. doi: 10.1007/BF00441955.